Driehaus Capital Management LLC Iveric Bio, Inc. Transaction History

Driehaus Capital Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$26.24 - $39.63 $9.61 Million - $14.5 Million	-366,230 Reduced 68.61%	167,588 $6.59 Million
Q1 2023 May 15, 2023	SELL	$18.67 - $24.56 $4.65 Million - $6.11 Million	-248,904 Reduced 31.8%	533,818 $13 Million
Q4 2022 Feb 14, 2023	BUY	$17.24 - $23.95 $538,439 - $748,006	31,232 Added 4.16%	782,722 $16.8 Million
Q3 2022 Nov 14, 2022	SELL	$9.4 - $18.59 $3.43 Million - $6.78 Million	-364,911 Reduced 32.69%	751,490 $13.5 Million
Q2 2022 Aug 15, 2022	BUY	$9.12 - $18.9 $2.48 Million - $5.13 Million	271,587 Added 32.15%	1,116,401 $10.7 Million
Q1 2022 May 16, 2022	SELL	$12.15 - $16.83 $197,158 - $273,100	-16,227 Reduced 1.88%	844,814 $14.2 Million
Q4 2021 Feb 14, 2022	SELL	$13.83 - $18.78 $987,337 - $1.34 Million	-71,391 Reduced 7.66%	861,041 $14.4 Million
Q3 2021 Nov 15, 2021	BUY	$7.07 - $17.5 $6.59 Million - $16.3 Million	932,432 New	932,432 $15.1 Million

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Driehaus Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Driehaus Capital Management LLC with notifications on news.